InspireMD Inc. (NSPR) News

InspireMD Inc. (NSPR): $4.69

0.05 (+1.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter NSPR News Items

NSPR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest NSPR News From Around the Web

Below are the latest news stories about InspireMD Inc that investors may wish to consider to help them evaluate NSPR as an investment opportunity.

InspireMD Reports Narrower Loss In Q2 As Revenue Rebounds On Procedural Recovery

InspireMD Inc (NASDAQ: NSPR ) has recorded a robust increase in second-quarter FY21 sales of $1.04 million, +231.6% Y/Y, slightly missing the consensus of $1.1 million. The Company posted a narrower EPS loss of $(0.46) compared to $(2.93) a year ago, beating the Full story available on Benzinga.com

Benzinga | August 10, 2021

InspireMD Announces Strong Second Quarter 2021 Financial Results

Revenue rebound, strong procedural recovery

Intrado Digital Media | August 10, 2021

InspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate Update

Earnings conference call to be held Tuesday, August 10, 2021, at 8:30 a.m. ET Earnings conference call to be held Tuesday, August 10, 2021, at 8:30 a.m. ET

Intrado Digital Media | August 4, 2021

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces the initiation of enrollment and successful completion of the first cases of the Companys U.S. registration C-Guardian trial of CGuard EPS.

Intrado Digital Media | July 23, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning!

William White on InvestorPlace | July 22, 2021

Should I Avoid InspireMD Inc (NSPR)?

No summary available.

Insider Monkey | June 13, 2021

InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq

Tickers to be NSPRW and NSPRZ Tickers to be NSPRW and NSPRZ

GlobeNewswire | May 27, 2021

InspireMD Announces Warrants Exchange Listing Transfer to NasdaqTickers to be NSPRW and NSPRZ

InspireMD, Inc., developer of the CGuard Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market.

BioSpace | May 26, 2021

InspireMD Announces Appointment of Katie Arnold to Board of Directors

TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced it has appointed seasoned marketing executive Kathryn (Katie) Arnold to its Board of Directors. With more than two decades of strategy and commercialization experience within the medical device industry, Ms. Arnold joins as the company advances global commercialization and enrollment in the U.S. IDE trial of its novel CGuard EPS technology. “We are pleased to welcome Katie to the InspireMD Board. She is a proven marketing professional with a track record for delivering flawless launch execution and implementing key business strategies,” comme...

Yahoo | May 12, 2021

InspireMD, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 11, 2021 / InspireMD, Inc. (AMEX:NSPR) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 11, 2021 at 8:30 AM Eastern Time.

Yahoo | May 11, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.743 seconds.